Mage Biologics

Mage Biologics is a special purpose company aimed at developing a novel oral monoclonal antibody for the treatment of ulcerative colitis. Mage Biologics is jointly funded by TVM Life Science Innovation II and Tillotts Pharma and led by an experienced management team.